Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.76 EUR
Change Today +0.04 / 5.52%
Volume 1.3K
O8Z1 On Other Exchanges
Symbol
Exchange
O8Z1 is not on other exchanges.
As of 1:17 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (O8Z1) Snapshot

Open
€0.72
Previous Close
€0.72
Day High
€0.76
Day Low
€0.72
52 Week High
04/3/14 - €3.11
52 Week Low
01/30/15 - €0.63
Market Cap
11.4M
Average Volume 10 Days
855.0
EPS TTM
--
Shares Outstanding
14.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCULUS INNOVATIVE SCIENCES I (O8Z1)

Related News

No related news articles were found.

oculus innovative sciences i (O8Z1) Related Businessweek News

No Related Businessweek News Found

oculus innovative sciences i (O8Z1) Details

Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of organisms that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human advanced wound and tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company’s Microcyn has received eight 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

31 Employees
Last Reported Date: 01/20/15
Founded in 1999

oculus innovative sciences i (O8Z1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $263.5K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $250.0K
Executive Vice President of International Ope...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

oculus innovative sciences i (O8Z1) Key Developments

Oculus Innovative Sciences, Inc. Receives Non-Compliance Notice From NASDAQ

On March 6, 2015, Oculus Innovative Sciences, Inc. received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC, notifying the company that, for the last 30 consecutive business days, the company failed to comply with NASDAQ Listing Rule 5550(a)(2), which requires to maintain a minimum bid price of $1.00 per share for common stock. In accordance with Listing Rule 5810(c)(3)(A), NASDAQ granted the company a compliance period of 180 calendar days, or until September 2, 2015, to regain compliance with the Listing Rule. If at any time during this 180 day period the closing bid price of the common stock is at least $1 for a minimum of 10 consecutive business days, the company will regain compliance with the Listing Rule and NASDAQ will close the matter. The letter has no effect on the listing or trading of the common stock at this time. However, there can be no assurance that the company will be able to regain compliance with Listing Rule 5550(a)(2). The company intends to cure the bid price compliance deficiency by effecting a reverse stock split, if necessary.

Oculus Innovative Sciences, Inc. Announces Launch of New Animal Healthcare Division

Oculus Innovative Sciences, Inc. announced the launch of the company's new animal healthcare division. In conjunction with the unveiling of the new division, six new MicrocynAH® advanced all-animal healthcare products were commercialized for the care of wounds, skin and eyes in the United States and Canadian markets.

Oculus Innovative Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Reports Impairment for the Third Quarter Ended December 31, 2014

Oculus Innovative Sciences, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the third quarter of fiscal year 2015, the company’s total revenue was $3.2 million for the third quarter as compared to $3.3 million for the same period in 2013. Net loss was $5.9 million, an increase of $5.3 million, as compared to net loss of $611,000 for the same period in the prior year. The increase is primarily due to an impairment loss recorded in the three months ended December 31, 2014, in the amount of $4,650,000, related to Oculus' investment in Ruthigen. Loss from operations was $1,949,000 compared to $1,546,000 a year ago. Net loss per common basic and diluted share was $0.69 compared to $0.09 a year ago. For the nine months, the company’s total revenues were $9.9 million, as compared to $10.8 million for the same period in the prior year. Loss from operations was $5,007,000 compared to $3,943,000 a year ago. Net loss was $6,702,000 or $0.79 per basic and diluted share, compared to $3,722,000 or $0.56 per basic and diluted share, a year ago. The company reported impairment for the third quarter ended December 31, 2014. For the third quarter, the company reported loss on impairment of investment held at cost of $4,650,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
O8Z1:GR €0.76 EUR +0.04

O8Z1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,924 JPY -43.50
Henry Schein Inc $139.62 USD -1.22
Integra LifeSciences Holdings Corp $61.65 USD -0.49
Patterson Cos Inc $48.79 USD -0.31
Smith & Nephew PLC 1,144 GBp -1.00
View Industry Companies
 

Industry Analysis

O8Z1

Industry Average

Valuation O8Z1 Industry Range
Price/Earnings 9.0x
Price/Sales 0.6x
Price/Book 0.9x
Price/Cash Flow 16.2x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit www.oculusis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.